Sichen Chang

发表

Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.

Bruce J. Melancon, Anna L. Blobaum, N. Brandon, 2017, ACS medicinal chemistry letters.

Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.

Bruce J. Melancon, N. Brandon, C. Lindsley, 2017, Bioorganic & medicinal chemistry letters.

Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.

N. Brandon, C. Lindsley, Hyekyung P. Cho, 2017, Bioorganic & medicinal chemistry letters.

Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.

Julie L. Engers, C. Lindsley, Hyekyung P. Cho, 2017, Bioorganic & medicinal chemistry letters.

Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.

Bruce J. Melancon, N. Brandon, C. Lindsley, 2017, Bioorganic & medicinal chemistry letters.

Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.

Julie L. Engers, C. Lindsley, P. Conn, 2021, ACS medicinal chemistry letters.

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809.

Wei Wang, Liping Tang, S. Rowe, 2019, Chemistry.

Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2017, ACS medicinal chemistry letters.

Discovery of a potent M5 antagonist with improved clearance profile. Part 1: piperidine amide-based antagonists.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2022, Bioorganic & medicinal chemistry letters.

Development and profiling of mGlu7 NAMs with a range of saturable inhibition of agonist responses in vitro.

Anna L. Blobaum, C. Lindsley, C. Niswender, 2022, Bioorganic & medicinal chemistry letters.

Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.

Anna L. Blobaum, C. Lindsley, P. Conn, 2017, ACS medicinal chemistry letters.

Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2017, ACS medicinal chemistry letters.

Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.

Bruce J. Melancon, N. Brandon, C. Lindsley, 2017, Bioorganic & medicinal chemistry letters.

Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.

N. Brandon, C. Lindsley, P. Conn, 2016, Bioorganic & medicinal chemistry letters.

Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.

Alison R. Gregro, Julie L. Engers, Bruce J. Melancon, 2016, Bioorganic & medicinal chemistry letters.

Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M5 Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder.

Andrew S. Felts, Anna L. Blobaum, N. Schnetz-Boutaud, 2022, Journal of medicinal chemistry.

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

S. P. Moran, Anna L. Blobaum, C. Lindsley, 2018, ACS chemical neuroscience.

First transition metal complex containing SMIA− carboxylate ligand: Synthesis, structure and magnetic properties of a new tetranuclear copper complex [Cu4(SMIA)6(phen)4](ClO4)2

Jie Ma, Sichen Chang, Chongqing Wan, 2019, Inorganic Chemistry Communications.

Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2017, ACS chemical neuroscience.

Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy.

Julie L. Engers, C. Lindsley, Hyekyung P. Cho, 2021, ACS pharmacology & translational science.

Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2015, Journal of medicinal chemistry.

Synthesis and Characterization of Chiral 6-Azaspiro[2.5]Octanes as Potent and Selective Antagonists of the M4 Muscarinic Acetylcholine Receptor

C. Lindsley, P. Conn, J. Harp, 2021, Bioorganic & Medicinal Chemistry Letters.

Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold.

Alice E. Berizzi, C. Langmead, P. Sexton, 2018, ACS chemical neuroscience.

Discovery of the first selective M4 muscarinic acetylcholine receptor antagonists with in vivo anti-parkinsonian and anti-dystonic efficacy

Julie L. Engers, C. Lindsley, P. Conn, 2020 .

Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2015, Journal of medicinal chemistry.

Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration.

Anna L. Blobaum, C. Lindsley, P. Conn, 2016, Bioorganic & medicinal chemistry letters.

Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M4 positive allosteric modulator (PAM) chemotype.

Julie L. Engers, C. Lindsley, C. Niswender, 2019, Bioorganic & medicinal chemistry letters.

Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes.

Julie L. Engers, C. Lindsley, C. Niswender, 2019, Bioorganic & medicinal chemistry letters.

SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs.

Alison R. Gregro, Andrew S. Felts, N. Schnetz-Boutaud, 2019, Bioorganic & medicinal chemistry letters.

Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.

C. Lindsley, Hyekyung P. Cho, P. Conn, 2017, Bioorganic & medicinal chemistry letters.

Discovery of a novel 3,4-dimethylcinnoline carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.

Alison R. Gregro, Julie L. Engers, C. Lindsley, 2019, Bioorganic & medicinal chemistry letters.

Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2017, Journal of medicinal chemistry.

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 4: SAR reveals positive cooperativity across multiple mGlu receptor subtypes leading to subtype unselective PAMs.

Anna L. Blobaum, O. Boutaud, C. Lindsley, 2020, Bioorganic & medicinal chemistry letters.

Discovery and optimization of 3-(4-aryl/heteroarylsulfonyl)piperazin-1-yl)-6-(piperidin-1-yl)pyridazines as novel, CNS penetrant pan-muscarinic antagonists.

C. Lindsley, Hyekyung P. Cho, P. Conn, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of a novel Kir6.2/SUR1 channel opener scaffold identified by HTS.

O. Boutaud, C. Lindsley, Joshua A. Bauer, 2023, Bioorganic & medicinal chemistry letters.

Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.

Alison R. Gregro, Julie L. Engers, C. Lindsley, 2017, Bioorganic & medicinal chemistry letters.

Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.

N. Brandon, C. Lindsley, P. Conn, 2017, ACS medicinal chemistry letters.